drugset
drugset / Trial / NCT02228395

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

NCT02228395 ↗

Phase 1 Completed 12 enrolled Biogen
RandomizedCrossoverDouble-blindBasic science

Summary

This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers

Timeline

Start
2014-09-22
Primary completion
2014-11-13
Completion
2014-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.35 mg Oral
Subject PESAMPATOR Small molecule 0.6 mg Oral
Subject PESAMPATOR Small molecule 0.8 mg Oral

Indications

No indication recorded.